Your session is about to expire
← Back to Search
Azacitidine + Quizartinib for Myelodysplastic Syndrome
Study Summary
This trial is testing the side effects and best dose of quizartinib when given with azacitidine to people with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 367 Patients • NCT02039726Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a serious heart rhythm problem but have a pacemaker.I have congenital long QT syndrome.I do not have active hepatitis B, hepatitis C, or HIV.I have been diagnosed with MDS or a related condition.I have had a heart attack in the last 6 months or have uncontrolled heart problems.I have used medications like hydroxyurea or growth factors for blood cell control.My heart's pumping ability is significantly reduced.I am a woman who can have children and have not had a negative pregnancy test.I have not used hypomethylating agents and my blood cancer is classified as intermediate-2 or higher, or I have specific genetic mutations.My heart's electrical activity is normal, with a QTcF interval of 450 msec or less.I have not used hypomethylating agents and my blood condition is considered high-risk.I am not on medication that affects heart rhythm, except for essential treatments.I did not respond to or my condition worsened after treatment with specific agents.I am able to care for myself and perform daily activities.I am not currently on any experimental treatments or undergoing chemotherapy, radiotherapy, or immunotherapy.I did not respond to or my condition worsened after treatment with specific agents.I am able to get out of my bed or chair and move around.I have been diagnosed with MDS or a related condition.My cancer has a specific genetic mutation (FLT3-ITD or CBL).I am currently taking medication that strongly affects liver enzyme activity.I have had a heart rhythm problem that needed treatment.I am not pregnant or breastfeeding.I have an infection that isn't getting better with antibiotics.I have a history of serious irregular heartbeats.My cancer has a specific genetic mutation (FLT3-ITD or CBL).
- Group 1: Treatment (azacitidine, quizartinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical indications typically warrant Quizartinib treatment?
"Quizartinib is a viable option for treating malignant neoplasms, neutropenia and/or thrombocytopenia with greater than 20-30% blasts."
What prior research exists on Quizartinib?
"Currently, there are 182 clinical trials examining the effects of Quizartinib with 33 at Phase 3. Despite Saint Louis hosting a considerable number of these studies, there is an aggregate of 6,024 medical centres conducting trial for this medication around the world."
Is enrollment open for this experiment?
"Indeed, according to clinicaltrials.gov this medical trial is actively looking for participants. The listing was originally created on July 21st 2020 and the most recent update happened on May 23rd 2022; 58 volunteers are needed at a single site."
What is the cohort size for this research initiative?
"Affirmative, the information available on clinicaltrials.gov states that this medical trial is currently looking for volunteers. The experiment was first published in July of 2020 and edited most recently in May 2022; 58 participants are required at a single site."
Share this study with friends
Copy Link
Messenger